Boundless Bio, Inc. — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
On August 28, 2026, Boundless Bio, Inc. (acquirer) and Serapha Bio, Inc. (target) amended their June 22, 2026 merger agreement. Key changes: (1) Company RSUs will convert to Parent RSUs at the Exchange Ratio; (2) Pre-Funded Warrants introduced for holders exceeding beneficial ownership limits (capped at 19.99%, default 9.99%), exercisable at $0.00001 per share; (3) clarified treatment of restricted stock units in equity incentive plans (5% reserve through pre-closing financing); (4) technical amendments to definitions and stockholder voting provisions. No dollar amounts or share counts disclosed in the amendment itself.
Why this rating
Material structural amendment to a pending merger at $18M market-cap company. RSU conversion and anti-dilution mechanisms via warrants are significant governance/capital structure changes affecting deal mechanics and shareholder economics, but filing is administrative amendment—not new value-creating event.
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.